病例报告：硼替佐米联合CDOP方案序贯自体造血干细胞移植及来那度胺维持治疗浆母细胞淋巴瘤
Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.
作者信息
Cai Jiao, Qiu Ling, Ma Lei, Zhang Nan, Fan Fang-Yi
机构信息
Department of Hematology and Hematopoietic Stem Cell Transplantation Centre, General Hospital of the Chinese People's Liberation Army Western Theater, Chengdu, China.
出版信息
Front Med (Lausanne). 2021 Dec 3;8:749863. doi: 10.3389/fmed.2021.749863. eCollection 2021.
The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.
浆母细胞淋巴瘤（PBL）患者的标准化治疗方案仍存在争议。考虑形态学特征和免疫表型可能为PBL的治疗提供更好的选择。在本病例中，我们报告一种包含硼替佐米联合环磷酰胺、表柔比星、长春地辛和泼尼松（CDOP）的骨髓瘤型方案，随后序贯自体造血干细胞移植（ASCT）和基于来那度胺的维持治疗来治疗PBL，可能是一种改善预后的有前景的方案。
Zotero 插件